Reference health
Risk Factors of Fluoropyrimidine Induced Cardiotoxicity among Cancer Patients: A Systematic Review and Meta-analysis
77/77 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
19 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 77 checked references that resolve
resolves10.1007/s10549-018-5053-y
Evaluation of radiation-induced cardiac toxicity in breast cancer patients treated with Trastuzumab-based chemotherapy
resolves10.1159/000227226
Symptomatic Cardiotoxicity with High-Dose 5-Fluorouracil Infusion: A Prospective Study
resolves10.1093/jnci/djp440
Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention
resolves10.1016/j.atherosclerosis.2017.04.009
Risk of incident myocardial infarction by gender: Interactions with serum lipids, blood pressure and smoking. The Tromsø Study 1979–2012
resolves10.1002/(SICI)1097-0258(19970415)16:7<753::AID-SIM494>3.0.CO;2-G
INCORPORATING VARIABILITY IN ESTIMATES OF HETEROGENEITY IN THE RANDOM EFFECTS MODEL IN META-ANALYSIS
resolves10.1016/j.ijrobp.2015.11.040
Cardiovascular Disease Risk in a Large, Population-Based Cohort of Breast Cancer Survivors
resolves10.1038/sj.bjc.6603059
Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial
resolves10.1111/j.1365-2710.2004.00556.x
Influence of high-dose leucovorin and 5-fluorouracil chemotherapy regimen on P wave duration and dispersion
resolves10.1111/j.0742-2822.2005.03169.x
Ultrasound Tissue Characterization by Integrated Backscatter for Analyzing Fluorouracil Induced Myocardial Damage
resolves10.1016/j.pharmthera.2005.09.002
Mechanisms of target organ damage caused by hypertension: Therapeutic potential
resolves10.1200/JCO.2012.43.3391
Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer
resolves10.1200/JCO.1992.10.11.1795
Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study.
resolves10.1093/annonc/mdu141
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer
resolves10.1111/j.0006-341X.2000.00455.x
Trim and Fill: A Simple Funnel‐Plot–Based Method of Testing and Adjusting for Publication Bias in Meta‐Analysis
resolves10.1186/s12885-019-5421-y
The heart’s exposure to radiation increases the risk of cardiac toxicity after chemoradiotherapy for superficial esophageal cancer: a retrospective cohort study
resolves10.1016/j.mayocp.2014.05.013
Evaluation and Management of Patients With Heart Disease and Cancer: Cardio-Oncology
resolves10.1016/j.ijcard.2012.09.052
Post-cardiac injury syndromes. An emerging cause of pericardial diseases
resolves10.1136/bmjopen-2015-010247
Plea for routinely presenting prediction intervals in meta-analysis
resolves10.18632/oncotarget.24724
Impact of tobacco smoking on the risk of developing 25 different cancers in the UK: a retrospective study of 422,010 patients followed for up to 30 years
resolves10.1016/S0149-2918(04)90060-4
Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands
resolves10.1007/s00280-005-0178-1
Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine
resolves10.1007/s00280-011-1669-x
5-Fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity
resolves10.1200/JCO.2009.27.3953
Fluorouracil Induces Myocardial Ischemia With Increases of Plasma Brain Natriuretic Peptide and Lactic Acid but Without Dysfunction of Left Ventricle
resolves10.1080/1120009X.1990.11739029
Cardiotoxicity During Chemotherapy Treatment with 5-Fluorouracil and Cisplatin
resolves10.1007/s00280-019-03888-1
Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients
resolves10.1200/JCO.2017.74.9739
New-Onset Cardiovascular Morbidity in Older Adults With Stage I to III Colorectal Cancer
resolves10.1016/S1470-2045(16)30172-3
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
resolves10.1093/annonc/mdl179
Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study
resolves10.1016/S0140-6736(07)61086-1
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial
resolves10.1007/s00432-007-0250-9
Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study
resolves10.1016/j.ejca.2017.02.009
Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group
resolves10.1007/s11912-016-0521-1
Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management
resolves10.2174/138161208784746699
Smoking and Cardiovascular System: Cellular Features of the Damage
resolves10.1093/annonc/mdu055
Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk
resolves10.1186/s12955-015-0261-1
Comparing the effectiveness of capecitabine versus 5-fluorouracil/leucovorin therapy for elderly Taiwanese stage III colorectal cancer patients based on quality-of-life measures (QLQ-C30 and QLQ-CR38) and a new cost assessment tool
resolves10.1016/j.ctrv.2016.08.002
Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity – Ready for clinical practice?
resolves10.1093/jjco/hyi071
Cardiotoxicity of de Gramont's Regimen: Incidence, Clinical Characteristics and Long-term Follow-up
resolves10.1016/j.ejca.2005.03.027
The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC)
resolves10.1080/0284186X.2017.1423375
Predictive factors of thromboembolic complications in patients with esophagogatric adenocarcinoma undergoing preoperative chemotherapy
resolves10.1016/j.jclinepi.2007.11.010
Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry
resolves10.1186/s12885-016-2409-8
TAS-102, the first “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape?
resolves10.5603/KP.a2016.0163
Tissue Doppler echocardiography detects subclinical left ventricular dysfunction in patients undergoing chemotherapy for colon cancer: insights from ONCOECHO multicentre study
resolves10.1016/j.ctrv.2013.03.005
Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factors
resolves10.1186/2050-6511-15-47
A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity
resolves10.1136/bmjopen-2016-012798
Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer
resolves10.1093/annonc/mdt479
Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines
resolves10.1200/JCO.2004.08.009
Four Decades of Continuing Innovation With Fluorouracil: Current and Future Approaches to Fluorouracil Chemoradiation Therapy
resolves10.3816/CBC.2007.n.050
Safety Profile and Activity of Lower Capecitabine Dose in Patients with Metastatic Breast Cancer
resolves10.4103/0973-1482.187303
Cardiotoxic effects of radiotherapy and strategies to reduce them in patients with breast cancer: An overview
resolves10.1002/1097-0142(19931001)72:7<2242::AID-CNCR2820720730>3.0.CO;2-E
Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer
resolves10.1634/theoncologist.2011-0235
Phase II Trial of Simple Oral Therapy with Capecitabine and Cyclophosphamide in Patients with Metastatic Breast Cancer: SWOG S0430
resolves10.1016/S0140-6736(14)62004-3
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
resolves10.1056/NEJMoa0808268
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
resolves10.1007/s10549-015-3441-0
Adjuvant taxane-based chemotherapy for early stage breast cancer: a real-world comparison of chemotherapy regimens in Ontario
resolves10.1371/journal.pone.0059202
The Impact of Study Size on Meta-analyses: Examination of Underpowered Studies in Cochrane Reviews
resolves10.2478/raon-2019-0046
Total neoadjuvant treatment of locally advanced rectal cancer with high risk factors in Slovenia
resolves10.1245/s10434-014-4120-9
Safety, Efficacy, and Long-Term Follow-Up Evaluation of Perioperative Epirubicin, Cisplatin, and Capecitabine Chemotherapy in Esophageal Resection for Adenocarcinoma
resolves10.2174/157340311799960645
Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
resolves10.1038/srep36060
Cost-effectiveness Analysis of Fluorouracil, Leucovorin, and Irinotecan versus Epirubicin, Cisplatin, and Capecitabine in Patients with Advanced Gastric Adenocarcinoma
resolves10.1007/s00066-012-0073-8
Simultaneous neoadjuvant radiochemotherapy with capecitabine and oxaliplatin for locally advanced rectal cancer
resolves10.1097/COC.0000000000000389
Prevention of Trastuzumab and Anthracycline-induced Cardiotoxicity Using Angiotensin-converting Enzyme Inhibitors or β-blockers in Older Adults With Breast Cancer
resolves10.1111/j.1742-1241.2007.01323.x
5-Fluorouracil increases the number and complexity of premature complexes in the heart: a prospective study using ambulatory ECG monitoring
resolves10.1080/13696998.2017.1296452
Cost minimization analysis of capecitabine versus 5-fluorouracil-based treatment for gastric cancer patients in Hong Kong
The 19 references without a DOI — listed, not checked
no DOI — not checked5-fluorouracil-related cardiotoxicity; findings from five randomized studies of 5-Fluorouracil-based regimens in metastatic colorectal Cancer
no DOI — not checked2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
no DOI — not checkedNCCN guidelines insights: colon Cancer, version 2.2018
no DOI — not checkedRectal Cancer, version 2.2018, NCCN clinical practice guidelines in oncology
no DOI — not checked10.1016/j.critrevonc.2021.103346_bib0055
no DOI — not checkedDerSimonian-Laird D., Paule-Mandel P., Maximum-likelihood M., et al. Doing Meta-Analysis in R.
no DOI — not checkedMeta-analysis in medical research
no DOI — not checkedCapecitabine in the management of colorectal cancer
no DOI — not checkedAdjuvant chemotherapy and risk of gastrointestinal, hematologic, and cardiac toxicities in elderly patients with stage III Colon Cancer
no DOI — not checkedFluoropyrimidine-associated cardiotoxicity
no DOI — not checkedA retrospective study of cardiotoxicities induced by 5-fluouracil (5-FU) and 5-FU based chemotherapy regimens in Pakistani adult cancer patients at Shaukat Khanum Memorial Cancer hospital & Research Center
no DOI — not checkedEfficacy and cardiotoxic safety profile of raltitrexed in fluoropyrimidines-pretreated or high-risk cardiac patients with GI malignancies: large single-center experience
no DOI — not checkedComparative cardiac toxicity in two treatment schedules of 5-FU/LV for colorectal carcinoma
no DOI — not checkedCardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study
no DOI — not checkedFluoropyrimidine-associated cardiotoxicity: a retrospective case-control study
no DOI — not checkedManagement of outpatients with cardiac disease: follow-up timing and modalities
no DOI — not checkedRecommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials
no DOI — not checkedStudy Quality Assessment Tools. Secondary Study Quality Assessment Tools. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools.
no DOI — not checkedFluoropyrimidine cardiotoxicity: time for a contemporaneous appraisal
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1016/j.critrevonc.2021.103346"><img src="https://citestamp.com/citestamped/10.1016/j.critrevonc.2021.103346/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1016/j.critrevonc.2021.103346)